Cumulative incidence of hematologic response by treatment group and depending on the severity of AA. (A) Cumulative incidence of OR by treatment group. (B) Cumulative incidence of CR by treatment group. (C) Cumulative incidence of OR in SAA (ANC ≥0.2 × 10⁹/L) patients by treatment group. (D) Cumulative incidence of OR in vSAA (ANC <0.2 × 10⁹/L) patients by treatment group. Shaded areas are 95% CIs. Competing events included death. The start of the second-line treatment with hATG/CsA ± ELTR and HSCT was considered censoring. P values are given for the 4-month point. The cumulative incidence of the overall response at 4 months was 65% (95% CI, 52-79) in the ELTR + IST group and 54% (95% CI, 40-69) in the IST group (A). The cumulative incidences for complete response at 4 months were 31% (95% CI, 18-44) and 13% (95% CI, 3-22), respectively (B). The cumulative incidence of the overall response at 4 months in patients with SAA (ANC ≥0.2 × 10⁹/L) was 89% (95% CI, 89-100) in the ELTR + IST group and 57% (95% CI, 35-79) in the IST group (C). The cumulative incidence of the overall response at 4 months in patients with vSAA (ANC <0.2 × 10⁹/L) was 52% (95% CI, 34-70) and 52% (95% CI, 33-72) (D).